VANCOUVER, British Columbia--(BUSINESS WIRE)--April 26, 2006--HepaLife Technologies, Inc. (OTCBB:HPLF - News; FWB:HL1), today announces that the Company’s PICM-19H liver cells have demonstrated the capability to fully survive and remain intact following exposure to human plasma, an important finding in the future integration of these cells into an artificial liver device for human use.
